Accelerating Rare disease Cures Program
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Points of contact
-
- tbd@fda.gov
- Christopher Scott christopher.scott@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration is forecasting the Accelerating Rare Disease Cures Program, a new requirement focused on scientific and technical consulting services in the rare disease domain. The solicitation is estimated to be released on November 1, 2025, with an anticipated contract award date of January 1, 2026. This opportunity falls under the NAICS code 541690 for Other Scientific and Technical Consulting Services, targeting organizations with expertise in rare disease research and development.
While specific award values and budget ranges are not currently disclosed, the program appears to be centered on advancing rare disease cures through the Office of New Drugs (OND). Potential contractors can expect to engage with the FDA through the provided contact points, including Christopher Scott (christopher.scott@fda.hhs.gov) and a general mailbox (tbd@fda.gov). The contract will likely involve comprehensive scientific consulting services aimed at supporting rare disease research, with the performance location expected to be within the FDA's operational jurisdiction.
Forecast text
Rare Disease Funding - OND's Advancing Rare Disease Cures Program
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast